Exchange Session 3 – Implement/Sustain
Review considerations for MOUD initiation and follow-up, including lab guidelines, and clinical management of patients with continued use (e.g., fentanyl, novel synthetic opioids), overdose risk, poly-substance use, and comorbid mental health conditions.
Exchange Session 2 – Prepare
Review patient screening considerations and discuss how OUD screening can be integrated into current clinic workflows. Discuss the training and certifications required for specific team members to implement MOUD. Highlight the critical role of Champions, and how to strategically select Champions to support MOUD implementation.
Exchange Session 1 – Explore
Review medications for opioid use disorders (MOUD), with a focus on buprenorphine treatment and its various formulations, and strategies for including harm reduction approaches into care. Discuss administrative, clinical and financial considerations, and provide resources for both prescribers and non-prescribers.
PCSS-MOUD 8 Hour MOUD Training
Email [email protected] for registration.
PCSS-MOUD 8 Hour MOUD Training
Email [email protected] for registration.
PCSS-MOUD 8 Hour MOUD Training
Email [email protected] for registration.
PCSS-MOUD 8 Hour MOUD Training
Email [email protected] for registration.
PCSS-MOUD 8 Hour MOUD Training
Email [email protected] for registration.
8 Hour MOUD Training
If interested in attending please contact [email protected]
Newly Approved Weekly and Monthly Buprenorphine: A Primer for Clinicians
Target Audience: This activity was developed to meet the needs of physicians, nurses and interprofessional healthcare providers. Discussion is designed to promote interactivity through an informal “round table” conversation. Attendees will be given the opportunity to speak directly with the presenter to ask questions and discuss issues. In support of improving patient care, American Academy […]
